Wells Fargo lowered the firm’s price target on Inspire Medical (INSP) to $195 from $198 and keeps an Equal Weight rating on the shares. On February 10, Inspire Medical reported Q4 profitability and gave 2025 EPS guide above consensus. Inspire V inventory build remains gating factor to full launch, the firm notes. CID investigation may be an overhang, adds Wells.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSP:
- Inspire Medical Systems: Balancing Strong Performance with Operational Challenges and Regulatory Risks
- Inspire Medical Systems: Strong Buy Rating Amid Growth Prospects and DOJ Investigation Challenges
- Inspire Medical Systems Reports Strong Growth in 2024
- Closing Bell Movers: Lattice Semi up 13% on earnings
- Inspire Medical discloses civil investigative demand from DOJ